Triazavirin

Triazavirin Ural Federal University, Russia developed antiviral drugs that act with RNA itself. Used in Russia as an anti-influenza drug, it has also been used to treat tick-borne encephalitis, also caused by RNA viruses. It is a nucleoside analogue of nucleic acid and an antiviral agent.

Triazavirin works by inhibiting the synthesis of viral RNA and DNA, as well as the replication of genomic segments. Triazin is also an effective protective agent against the stages of influenza transmission.

Currently in Russia, CIS countries are also being used for COVID-19 treatment. Sales are expected to reach 10-15 million in 2022.

Product Name: Sodium 2-methylthio-6-nitro-1,2,4-triazol [5,1c][1,2,3]-triazin-7-one dihydrate

Synonyms: Sodium 2-methylthio-6-nitro-1,2,4-triazol [5,1c][1,2,3]-triazin-7-one dihydrate;1,2,4]Triazolo[5,1-c][1,2,4]triazin-4(6H)-one, 7-(methylthio)-3-nitro-, sodium salt, hydrate;Triazavirin;Sodium 7-(methylthio)-3-nitro-4-oxo-4H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-6-ide dihydrate;Triazavirin (Riamilovir);Triazavirin sodium hydrate (TZV, Riamilovir)

CAS: 928659-17-0

MF: C5H7N6NaO4S

MW: 270.2